FDAnews Device Daily Bulletin

Synthes Executive Pleads Guilty to Misdemeanor

Aug. 31, 2009
The final Synthes executive charged in connection with off-label promotion of Norian XR and unauthorized clinical trials has pleaded guilty to a misdemeanor of introducing the misbranded bone void filler into interstate commerce. Richard Bohner, head of Operations U.S. for Synthes, entered the plea as part of a plea agreement. His sentencing is set for Nov. 5. The other three officials charged in the case — Michael Huggins, John Walsh and Thomas Higgins — pleaded guilty to the same misdemeanor charge last month in separate agreements and are to be sentenced in October.
Device and Diagnostics Letter